TELA Bio, Inc. TELA

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
52/100
Moderate

About TELA Bio, Inc.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in … Full TELA analysis →

Competitive advantage assessment

Key strengths

  • Stable Gross Margin Profile Gross margin stability is strong (score 0.72). Low volatility confirms durable consumable pricing.
  • Improving FCF Trend FCF trend score is positive (score 0.74). Improving FCF margin signals compounding operational leverage.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.26). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Elevated Leverage Leverage is elevated vs peers (score 0.05). High net debt/EBITDA limits the balance sheet's acquisition firepower.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
67

Where TELA ranks in Medical Devices

TELA Bio, Inc. ranks #65 of 160 scored companies in Medical Devices by moat score — the top 41%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

Moat scores for companies ranked near TELA in Medical Devices
# Company Moat score Rating
61 PROCEPT BioRobotics Corporation PRCT 53/100 Moderate
62 CeriBell, Inc. CBLL 53/100 Moderate
63 Cytosorbents Corporation CTSO 52/100 Moderate
64 Inogen, Inc INGN 52/100 Moderate
65 TELA Bio, Inc. TELA 52/100 Moderate
66 electroCore, Inc. ECOR 51/100 Moderate
67 Venus Concept Inc. VERO 51/100 Moderate
68 Aethlon Medical, Inc. AEMD 51/100 Moderate
69 Apyx Medical Corporation APYX 51/100 Moderate

See every Medical Devices & Diagnostics company ranked by moat score →

How TELA scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 67 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 39 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 59 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 62 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 28 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 32 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding TELA's moat

What is TELA Bio, Inc.'s moat score?

TELA Bio, Inc. (TELA) scores 52 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #65 of 160 scored companies in Medical Devices, the top 41%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Pricing Power & Consumable Moat (67/100) and its weakest is Capital Structure & Resilience (28/100).

How does TELA Bio, Inc. compare with other Medical Devices companies?

TELA Bio, Inc. ranks #65 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are Inogen, Inc (INGN) at 52 just above it and electroCore, Inc. (ECOR) at 51 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is TELA Bio, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for TELA Bio, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and TELA scores: Pricing Power & Consumable Moat (67), R&D Pipeline & Capital Returns (39), FCF Quality & Cash Conversion (59), Commercial Execution (62), Capital Structure & Resilience (28), Growth Durability (32). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000